NCT02414776终止1 期
Phase Ib/II Study of Hydroxychloroquine in Metastatic ER-Positive Breast Cancer Progressing on Hormonal Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Number of Participants with Adverse Events as a Measure of the safety profile of orally administered hydroxychloroquine with hormonal therapy
研究概览
简要总结
To determine the safety and tolerability of orally administered hydroxychloroquine with hormonal therapy.
To assess the response rate of hydroxychloroquine in combination with hormonal therapy.
详细描述
To determine the number of patients with adverse effects
To assess the clinical response to the combination
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥ 18 years of age with histologically confirmed, metastatic ER + breast cancer with clinical progression of disease (including radiographically stable disease with at least 50% increment of an elevated tumor marker by two measurements at least 2 weeks apart (this particular tumor marker will be used for disease status assessment in the study) on current hormonal therapy with PFS for at least 3 months.
- •Karnofsky Performance Status (KPS) ≥70% and a life expectancy >3 months.
- •Participants must have at least one target visceral lesion that allows for evaluation of tumor response or in the case of bone-only metastases, patients need to have a positive imaging study such as bone scan, magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT) or CT, and an elevated tumor marker at least twice as high as upper limit.
- •Absolute neutrophil count > 1500 mm3, platelet count ≥ 80×109 L, hemoglobin ≥ 8.5 g/dL
- •Creatinine clearance ≥ 30 mL/min, total bilirubin ≤ 2 mg/dL, AST/ALT ≤ 3 times the upper limit of normal range
- •No remaining grade 2 or higher toxicity from prior cancer therapies unless judged to be clinically insignificant by the Principal Investigator
- •At least two (2) weeks from prior major surgery
- •Willingness to provide permission to biopsy one of the lesions if applicable before the study (All the patients are encouraged to have post-therapy biopsy upon progression of disease, but it is optional) as well as blood samples for pertinent laboratory studies
- •Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable non-hormonal contraceptive method (abstinence, or double barrier method) for the duration of the study and for 30 days following the last dose of study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial -
排除标准
- •On combination hormonal therapy with everolimus or any other investigational agent
- •Patients have symptomatic untreated brain metastasis or leptomeningeal metastases or treated but still symptomatic requiring the use of steroid 18Jul2014 Protocol v3: ABC 01 Anti-Autophagy for Met Breast Cancer Page 4 of 16
- •Lymphangitic carcinomatosis involving ≥ 50% of the lungs; evidence of metastases involving more than one third of the liver on sonogram or computed tomography
- •Lactating females
- •Uncontrolled cardiac disease, congestive heart failure, angina or hypertension
- •Myocardial infarction or unstable angina within 2 months of treatment
- •Known human immunodeficiency virus (HIV) infection or chronic active Hepatitis B or C (patients are NOT required to be tested for the presence of such viruses prior to therapy on this protocol)
- •Active clinically serious infection > CTCAE (version 4.03) Grade 2
- •Serious non-healing wound, ulcer, or bone fracture
- •Concurrent psychiatric illness/social situations that would limit safety and compliance with study requirements
- •Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements
- •Currently receiving any other investigational therapeutic agents
- •Patients with known glucose-6-phosphate dehydrogenase deficiency, porphyria, cirrhosis or any other conditions with potential significant known risks
- •Patients with history of retinal damage
研究组 & 干预措施
hydroxychloroquine plus hormonal therapy
Experimental
Add hydroxychloroquine to the current hormonal therapy
干预措施: hydroxychloroquine (Drug)
结局指标
主要结局
Number of Participants with Adverse Events as a Measure of the safety profile of orally administered hydroxychloroquine with hormonal therapy
时间窗: 18 months
Assess the dose-limiting side effects such as neutropenia, anemia, or thormbocytopenia, or non-hematologic side effects nausea, vomiting, diarrhea, or vision problems at the study dose
次要结局
- The recommended phase 2 clinical dose (RP2D) of orally administered hydroxychloroquine with hormonal therapy(18 months)
- The anti-tumor activity of hydroxychloroquine with hormonal therapy with clinical benefit rate (CBR). Clinical benefits are defined as complete remission (CR), partial remission (PR) and stable disease (SD)(18 months)
- The disease-free survival (DFS) when adding hydroxychloroquine to hormonal therapy(18 months)
- The pharmacodynamic (PD) profile of hydroxychloroquine with hormonal therapy(18 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)Alport Syndrome, X-LinkedNCT04937907Shanghai Children's Hospital50
已完成
2 期
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate CancerProstate Cancer RecurrentNCT04011410Patrick Hensley20
已完成
1 期
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaNCT01689987OHSU Knight Cancer Institute18
进行中（未招募）
1 期
Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative ColitisUlcerative Colitis (Disorder)NCT05119140Icahn School of Medicine at Mount Sinai3
已完成
3 期
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).Pulmonary SarcoidosisNCT02200146University of Milano Bicocca94